Gene control company, Synpromics, and life sciences company, Solid Biosciences, have entered into a research partnership for the development of new treatment options for Duchenne muscular dystrophy (DMD).
Partnership
Under the terms of the agreement, Synpromics will provide Solid Biosciences with access to a set of key muscle-selective promoter candidates to enhance its investigational gene therapy candidates for DMD treatment. The muscle-selective promoters, which have been designed with Synpromics’ PromPT technology, will be evaluated by Solid Biosciences for optimal product specific gene control.
“We are excited to leverage our PromPT technology platform to generate promoter candidates closely matching the precise criteria and specific product requirements for Solid Biosciences’ muscle gene medicine programme in Duchenne,” commented David Venables, CEO of Synpromics. “The collaboration between the scientific teams will enable the effective and rapid in vivo evaluation of the candidate promoters as compared to industry standards.”
“Synpromics’ cutting-edge technology has the potential to enhance our gene therapy development efforts, helping us to fulfil our promise to bring meaningful therapies to all patients with this devastating disease,” said Joel Schneider, PhD, chief technology officer, head of Exploratory R&D at Solid Biosciences. “This type of collaboration is key for building our next-generation gene therapy portfolio as we focus on enhancing fundamental aspects of our gene delivery and protein expression capabilities.”